| Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer A Woolston, K Khan, G Spain, LJ Barber, B Griffiths, R Gonzalez-Exposito, ... Cancer cell 36 (1), 35-50. e9, 2019 | 214 | 2019 |
| Ultra-sensitive mutation detection and genome-wide DNA copy number reconstruction by error-corrected circulating tumor DNA sequencing S Mansukhani, LJ Barber, D Kleftogiannis, SY Moorcraft, M Davidson, ... Clinical chemistry 64 (11), 1626-1635, 2018 | 53 | 2018 |
| Exclusion of gastrointestinal cancer patients with prior cancer from clinical trials: is this justified? EC Smyth, N Tarazona, C Peckitt, E Armstrong, S Mansukhani, ... Clinical colorectal cancer 15 (2), e53-e59, 2016 | 28 | 2016 |
| Detecting and tracking circulating tumour DNA copy number profiles during first line chemotherapy in oesophagogastric adenocarcinoma M Davidson, LJ Barber, A Woolston, C Cafferkey, S Mansukhani, ... Cancers 11 (5), 736, 2019 | 17 | 2019 |
| Iconic: Peri-operative immuno-chemotherapy in operable oesophageal and gastric cancer. S Mansukhani, M Davidson, A Gillbanks, C Peckitt, A Musallam, R Begum, ... Journal of Clinical Oncology 36 (15_suppl), TPS4139-TPS4139, 2018 | 6 | 2018 |
| Primary results of the ICONIC phase 2 trial of perioperative FLOT plus avelumab (FLOT-A) in operable oesophagogastric adenocarcinoma (OGA). A Gordon, B Challoner, A Athauda, A Woolston, S Mansukhani, ... Journal of Clinical Oncology 41 (4_suppl), 446-446, 2023 | 4 | 2023 |
| Molecular subtypes and novel genetic mechanisms of primary and acquired anti-EGFR resistance in colorectal cancer in the Prospect C biomarker trial KH Khan, A Woolston, G Spain, L Barber, Y Patil, B Griffiths, ... Cancer research 78 (13_Supplement), 4339-4339, 2018 | 2 | 2018 |
| Circulating tumor DNA for recurrence prediction and efficacy analysis in the ICONIC trial of peri-operative FLOT and avelumab (PD-L1) in localized esophago-gastric adenocarcinoma M Gerlinger, A Gordon, LJ Barber, G Laliotis, A Athauda, B Challoner, ... Cancer Research 83 (7_Supplement), 5591-5591, 2023 | 1 | 2023 |
| Exclusion of patients with prior cancers from clinical trials: Is this justified? N Tarazona, EC Smyth, E Armstrong, C Peckitt, S Mansukhani, I Chau Journal of Clinical Oncology 32 (15_suppl), 6544-6544, 2014 | 1 | 2014 |
| Radical radiotherapy for muscle-invasive bladder cancer: A single centre experience. M Forster, A Mehta, A Clifford, S Needleman, S Mansukhani, M Prentice Journal of Clinical Oncology 41 (6_suppl), 519-519, 2023 | | 2023 |
| Next generation circulating tumour DNA detection and subclonality analysis for gastrointestinal cancer therapy personalisation S Mansukhani Institute of Cancer Research (University Of London), 2021 | | 2021 |
| Perioperative FLOT+ anti-PD-L1 avelumab (FLOT-A) chemo-immunotherapy in resectable oesophagogastric adenocarcinoma (OGA): Safety and biomarker data from the ICONIC trial safety … M Davidson, S Mansukhani, N Starling, I Chau, D Watkins, ... Annals of Oncology 30, v254, 2019 | | 2019 |
| Ultra-sensitive mutation detection and genome-wide DNA copy 11 number reconstruction by error corrected circulating tumor DNA 12 sequencing 13 S Mansukhani, LJ Barber, D Kleftogiannis, S Yu, MD Moorcraft, ... | | |
